๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Industry-sponsored studies with a US investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9110 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:16 UTC
9110
Studies in scope
industry-sponsored, all four open statuses
4947
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 130 Florida 117 Georgia 69 Colorado 64 Illinois 63
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca299 Novartis Pharmaceuticals202 Eli Lilly and Company190 Merck Sharp & Dohme LLC183 AbbVie172 Clear sponsor filter
State
California130 Florida117 Georgia69 Colorado64 Illinois63
All 48 states
Target enrolment
to
183 of 9110 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-06-05
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
600
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Merck Sharp & Dohme LLC
Phase 3
400
Michigan, North Carolina, Ohio, Pennsylvania
2024-05-23
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Florida, Maryland, New Jersey, Ohio, Wisconsin
2024-05-20
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
Merck Sharp & Dohme LLC
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, North Dakota
2024-05-03
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,200
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2024-04-14
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 2
272
California, Connecticut, Massachusetts, New York, North Carolina, Pennsylvania, Texas
2024-04-10
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
780
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-04-03
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
Merck Sharp & Dohme LLC
Phase 1/2
230
California, Florida, Illinois, Iowa, New York, North Carolina, Ohio, Pennsylvania
2024-03-28
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
Merck Sharp & Dohme LLC
Phase 3
1,310
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Louisiana
2023-12-31
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
Merck Sharp & Dohme LLC
Phase 3
340
Arizona, California, Colorado, Massachusetts, Michigan, Nevada, New York, North Carolina
2023-12-31
Active, closed
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
Arizona, California, Colorado, Florida, Georgia, Kentucky, Maine, Massachusetts
2023-12-15
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana
2023-12-13
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 3
1,020
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-10-25
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
Merck Sharp & Dohme LLC
Phase 3
14,550
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-10-09
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic
Merck Sharp & Dohme LLC
Phase 3
735
Arkansas, California, Florida, Indiana, Maryland, Mississippi, Missouri, Montana
2023-08-08
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
Merck Sharp & Dohme LLC
Phase 3
1,089
Arkansas, California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts
2023-07-19
Active, closed
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1
95
Illinois, Kentucky, New Jersey
2023-07-06
Active, closed
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Merck Sharp & Dohme LLC
Phase 1/2
390
California, Colorado, Georgia, Indiana, Massachusetts, Missouri, New York, North Carolina
2023-06-23
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
Merck Sharp & Dohme LLC
Phase 2/3
342
California, Colorado, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-05-31
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
230
Arizona, California, New York, Pennsylvania
2023-05-16
Active, closed
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
NCT05766501HIV Infection
Merck Sharp & Dohme LLC
Phase 3
641
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Missouri, New Jersey
2023-03-17
Active, closed
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
300
Arkansas, Florida, Mississippi, Washington
2023-03-16
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Michigan
2023-03-16
Active, closed
DOR/ISL in HIV-1 Antiretroviral Treatment-naรฏve Participants (MK-8591A-053)
NCT05705349HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
537
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2023-03-08
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
NCT05631093HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
553
California, District of Columbia, Florida, Georgia, New Jersey, Pennsylvania, Texas
2023-02-20
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
NCT05630755HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
514
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-02-17
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
377
Arizona, Florida, Illinois, Indiana, Kentucky, Mississippi, Missouri
2023-02-14
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
614
Alabama, California, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2023-02-06
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC
Phase 2
42
California, Colorado, District of Columbia, Ohio, Pennsylvania, Tennessee, Washington, Wisconsin
2023-01-19
Recruiting
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
NCT05562830Urothelial Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
48
California, Colorado, Illinois, Indiana, Missouri, New York, Ohio, Pennsylvania
2022-11-16
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
60
District of Columbia, Illinois, Massachusetts, Utah
2022-08-10
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Alaska, Arizona, Colorado, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2022-07-21
Active, closed
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
NCT05382325Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC
Phase 1
70
South Dakota, Texas
2022-06-16
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 3
460
Alabama, California, Florida, Indiana, Massachusetts, Michigan, Mississippi, Pennsylvania
2022-03-24
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,800
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Maryland
2022-03-15
Recruiting
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
NCT04665037Invasive Fungal Infection
Merck Sharp & Dohme LLC
Phase 2
40
California, Florida, Illinois, North Carolina, Texas
2022-02-22
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2022-02-03
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
290
Arizona, California, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2022-01-14
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1
830
Florida, Michigan, New Jersey, New York, Virginia, Wisconsin
2021-12-17
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2021-12-13
Active, closed
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
NCT04980872PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Merck Sharp & Dohme LLC
Phase 2
60
Georgia, Massachusetts, Ohio, Texas, Washington
2021-11-02
Active, closed
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
NCT04776252HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
2,000
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Missouri, New Jersey
2021-09-15
Active, closed
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT04938817Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
110
Arizona, Georgia, Indiana, Kentucky, Maryland, Nebraska, Ohio, Pennsylvania
2021-08-19
Active, closed
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
NCT04976634Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
730
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Michigan, New York
2021-08-18
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
Merck Sharp & Dohme LLC
Phase 2
355
California, Illinois, Iowa, Maryland, Massachusetts, Michigan, Missouri, New York
2021-08-12
Active, closed
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
NCT04956692Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
531
Arkansas, California, Florida, Indiana, Kentucky, Missouri, Montana, New York
2021-08-05
Active, closed
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
NCT04895722Colorectal Cancer
Merck Sharp & Dohme LLC
Phase 2
302
Florida, Georgia, Illinois, New York, Pennsylvania, Tennessee, Texas, Washington
2021-06-25
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2021-06-18
Recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC
Phase 3
815
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Kentucky, Maryland
2021-05-12
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
808
Arizona, California, Colorado, Florida, Indiana, Iowa, Kentucky, New York
2021-04-21
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,854
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2021-04-14
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Arkansas, California, Colorado, Kentucky, Minnesota, New Jersey, North Dakota, Texas
2021-04-05
Active, closed
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
NCT04708041Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
700
California, Florida, South Carolina, Texas, Washington
2021-03-15
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
747
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky
2021-02-25
Recruiting
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
NCT04375800Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC
Phase 2
84
Colorado, Georgia
2021-02-03
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2021-01-10
Active, closed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
370
California, Connecticut, Illinois, Iowa, Michigan, New York, North Carolina, Pennsylvania
2020-12-17
Active, closed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
400
California, Connecticut, Illinois, Iowa, Michigan, New York, North Carolina, Pennsylvania
2020-12-16
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naรฏve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
672
Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kentucky, Louisiana
2020-12-08
Active, closed
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 2
154
District of Columbia, Florida, Kentucky, Maryland, Nebraska, New York, Pennsylvania, South Dakota
2020-09-13
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
870
Alabama, Arkansas, California, Florida, Indiana, Kentucky, Massachusetts, Michigan
2020-07-06
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185Urinary Bladder Neoplasms
Merck Sharp & Dohme LLC
Phase 3
520
District of Columbia, Florida, Kentucky, Maryland, Missouri, New Jersey, New York, Ohio
2020-05-19
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
755
Alabama, California, Colorado, District of Columbia, Georgia, Illinois, Louisiana, Maryland
2020-02-27
Active, closed
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
NCT04199689Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
6,033
California, Florida, Georgia, Idaho, Kansas, Kentucky, Missouri, Nevada
2020-02-27
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naรฏve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT04165070Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 1/2
450
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Recruiting
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165798Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Observational
1,065
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Active, closed
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895Urinary Bladder Cancer, Muscle-invasive
Merck Sharp & Dohme LLC
Phase 3
595
Alabama, Arkansas, California, Colorado, District of Columbia, Georgia, Illinois, Indiana
2019-07-24
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-12-27
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
1,397
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2018-12-24
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
Merck Sharp & Dohme LLC
Phase 3
714
California, Colorado, District of Columbia, Florida, Idaho, Illinois, Kansas, Kentucky
2018-12-17
Active, closed
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895Advanced Solid Neoplasms
Merck Sharp & Dohme LLC
Phase 2
329
Arizona, California, Colorado, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2018-12-12
Active, closed
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836Melanoma
Merck Sharp & Dohme LLC
Phase 3
976
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2018-09-12
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2018-08-21
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana
2018-04-24
Active, closed
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144Hodgkin Lymphoma
Merck Sharp & Dohme LLC
Phase 2
340
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2018-04-09
Recruiting
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
Merck Sharp & Dohme LLC
Phase 1/2
370
Colorado, Illinois, Massachusetts, New York, North Dakota, South Dakota, Texas
2015-03-19
Rows per page Showing 101–183 of 183
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-usa?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.